Study guide

8.2 Anemias: Classification, Iron Deficiency, Megaloblastic, Hemolytic, and Hemoglobinopathies

Philippine Medical Technologists Licensure Examination MTLE

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Clinical Chemistry: Laboratory Operations, Instrumentation, Reagents, Quality Assurance, and Safety

1.1 Specimen Collection, Preanalytical Variables, and Interferences 1.2 Clinical Chemistry Instrumentation, Photometry, and Automation 1.3 Quality Control, Westgard Rules, Calibration, and Laboratory Mathematics 1.4 Reagent Preparation, Laboratory Water, Glassware, Pipettes, and Centrifuges 1.5 Laboratory Safety: Chemical, Fire, Electrical, Biological, and Physical Hazards

2 Chapter 2: Clinical Chemistry: Carbohydrates, Lipids, Proteins, Non-Protein Nitrogen, and Liver Function

2.1 Glucose Homeostasis, Diagnostic Criteria for Diabetes Mellitus, and Glycemic Monitoring 2.2 Lipids, Lipoproteins, Apolipoproteins, and Coronary Heart Disease Risk Assessment 2.3 Serum Proteins, Albumin, Globulins, and Serum Protein Electrophoresis Patterns 2.4 Non-Protein Nitrogen Compounds: Urea, Creatinine, Uric Acid, and Renal Function 2.5 Liver Function Tests, Bilirubin Metabolism, and Jaundice

3 Chapter 3: Clinical Chemistry: Electrolytes, Blood Gases, Enzymology, Endocrinology, and Toxicology

3.1 Water Balance, Electrolytes, Osmolality, and Anion Gap Calculations 3.2 Blood Gas Analysis, Oxygenation, and Acid-Base Homeostasis 3.3 Clinical Enzymology: Enzyme Kinetics, Cardiac Biomarkers, and Hepatic and Pancreatic Enzymes 3.4 Endocrinology: Hormone Physiology and Endocrine Function Testing 3.5 Therapeutic Drug Monitoring and Clinical Toxicology

4 Chapter 4: Bacteriology: Specimen Management, Media, Staining, and Biosafety

4.1 Specimen Collection, Transport, Processing, and Microscopic Staining 4.2 Culture Media Classification, Quality Control, and Inoculation Techniques 4.3 Sterilization, Disinfection, Decontamination, and Biosafety Containment 4.4 Antimicrobial Susceptibility Testing Methods, Standardization, and Resistance Mechanisms

5 Chapter 5: Diagnostic Bacteriology: Major Pathogenic Bacteria

5.1 Medically Important Gram-Positive Cocci: Staphylococci, Streptococci, and Enterococci 5.2 Medically Important Gram-Negative Bacilli: Enterobacterales and Non-Fermenters 5.3 Fastidious, Microaerophilic, and Anaerobic Bacteria 5.4 Mycobacteria, Spirochetes, Atypical Bacteria, and Public Health Microbiology

6 Chapter 6: Medical Parasitology, Mycology, and Diagnostic Virology

6.1 Stool Examination Techniques and Intestinal Nematodes 6.2 Tissue Nematodes, Filarial Worms, Cestodes, and Trematodes 6.3 Medical Protozoology: Intestinal, Urogenital, and Blood/Tissue Protozoa 6.4 Medical Mycology: Yeasts, Dermatophytes, Dimorphic Fungi, and Opportunistic Molds 6.5 Clinical Virology: Viral Structure, Specimen Handling, and Diagnostic Methods

7 Chapter 7: Hematology: Specimen Collection, Routine Parameters, Instrumentation, and Manual Methods

7.1 Blood Specimen Collection, Anticoagulants, Preanalytical Variables, and Specimen Quality 7.2 Automated Cell Counting Principles, Complete Blood Count Parameters, and Erythrocyte Indices 7.3 Reticulocyte Evaluation, Supravital Staining, and Erythrocyte Sedimentation Rate 7.4 Manual Cell Counts, Manual Hemoglobin Methods, and Hematology Quality Control

8 Chapter 8: Hematology: Blood Cell Morphology, Bone Marrow, and Hematologic Disorders

8.1 Normal Erythropoiesis and Erythrocyte Morphologic Abnormalities 8.2 Anemias: Classification, Iron Deficiency, Megaloblastic, Hemolytic, and Hemoglobinopathies 8.3 Normal Leukopoiesis, Leukocyte Differential, and Non-Malignant White Cell Alterations 8.4 Hematologic Malignancies: Acute and Chronic Leukemias, Myeloproliferative and Lymphoproliferative Disorders 8.5 Peripheral Blood Smear Preparation and Staining, Bone Marrow Examination, and Cytochemistry

9 Chapter 9: Hemostasis: Coagulation and Platelet Function Testing and Hemostatic Disorders

9.1 Mechanisms of Primary and Secondary Hemostasis, Fibrinolysis, and Natural Inhibitors 9.2 Coagulation Laboratory Testing: PT/INR, aPTT, Fibrinogen, Thrombin Time, and Mixing Studies 9.3 Hemostatic and Thrombotic Disorders: Hemophilias, von Willebrand Disease, DIC, and Thrombophilias 9.4 Bleeding Time, Clotting Time, Platelet Function, and Special Hematology Tests

10 Chapter 10: Immunohematology: Blood Group Systems and Antiglobulin Testing

10.1 The ABO Blood Group System, Genetics, Subgroups, and Forward/Reverse Typing Discrepancies 10.2 The Rh Blood Group System, Weak D Testing, and Other Major Blood Group Systems 10.3 Antiglobulin Testing, Elution, Adsorption, and Special Antibody Procedures

11 Chapter 11: Blood Banking: Donor Operations, Component Therapy, and Adverse Reactions

11.1 Donor Selection, Physical Examination, Screening, and Mandatory Infectious Marker Testing 11.2 Blood Component Preparation, Storage, Expiration, and Indications for Transfusion 11.3 Pre-Transfusion Compatibility Testing and Transfusion Reactions 11.4 Hemolytic Disease of the Fetus and Newborn (HDFN) and Rh Immune Globulin

12 Chapter 12: Clinical Serology and Immunology

12.1 Principles of Immunology: Antigens, Antibodies, Complement, and Immune Responses 12.2 Serologic Testing Methodologies: Agglutination, Precipitation, Flocculation, and Labeled Immunoassays 12.3 Infectious Disease Serology: Syphilis, Viral Hepatitis Markers, HIV, Dengue, and Febrile Agglutinins 12.4 Autoimmune Serology, Hypersensitivity, Immunodeficiencies, and Histocompatibility (HLA)

13 Chapter 13: Clinical Microscopy: Urinalysis and Renal Pathology

13.1 Renal Physiology, Urine Formation, and Physical Examination of Urine 13.2 Chemical Examination of Urine: Reagent Strip Principles, Interferences, and Confirmatory Tests 13.3 Microscopic Examination of Urine Sediment: Cells, Casts, Crystals, and Contaminants 13.4 Renal Calculi, Glomerular/Tubular/Interstitial Renal Diseases, and Urinalysis Quality Control

14 Chapter 14: Clinical Microscopy: Body Fluids, Fecal Analysis, and Gastric, Duodenal, and Respiratory Specimens

14.1 Cerebrospinal Fluid Analysis: Collection, Cell Counts, Chemistry, and Microbiology 14.2 Serous Fluids (Pleural, Pericardial, Peritoneal: Transudates vs Exudates) and Synovial Fluid Analysis 14.3 Seminal Fluid and Amniotic Fluid Analysis 14.4 Fecal Analysis: Macroscopic, Microscopic, and Chemical Examination of Stool 14.5 Gastric Fluid, Duodenal Contents, Sputum, and Bronchoalveolar Specimens

15 Chapter 15: Histopathologic Techniques and Cytotechnology

15.1 Tissue Preservation, Fixation, Decalcification, and Processing Steps 15.2 Microtomy, Sectioning Artifacts, Hematoxylin and Eosin Staining, and Special Stains 15.3 Cytotechnology: Specimen Collection, Fixation, Papanicolaou Staining, and the Bethesda System 15.4 Special Procedures: Frozen Sections, Special Embedding, Immunohistochemistry, Electron Microscopy, Autopsy, Museum Techniques, and Laboratory Records

16 Chapter 16: Medical Technology Laws, Related Laws, and Ethics

16.1 Republic Act No. 5527 (The Philippine Medical Technology Act of 1969) and Key Amendments 16.2 Related Philippine Healthcare Laws, Code of Ethics, and Bioethics

8.2 Anemias: Classification, Iron Deficiency, Megaloblastic, Hemolytic, and Hemoglobinopathies

Key Takeaways Explain This Topic AI

Microcytic hypochromic anemias are differentiated using serum iron indices: Iron Deficiency Anemia exhibits depleted ferritin (<15 ng/mL), elevated TIBC, and high RDW; Anemia of Chronic Disease exhibits elevated hepcidin, normal-to-high ferritin, and low TIBC; while Beta-Thalassemia Minor displays an elevated RBC count (>5.0 x 10^12/L), normal RDW, and a Mentzer Index < 13.

Megaloblastic macrocytic anemia arises from impaired DNA synthesis causing nuclear-cytoplasmic dyssynchrony, oval macrocytes, and neutrophil hypersegmentation; Vitamin B12 deficiency is definitively distinguished from folate deficiency by elevated methylmalonic acid (MMA) and progressive subacute combined degeneration of the spinal cord.

Intravascular hemolysis destroys erythrocytes within the circulation, producing marked hemoglobinemia, profound haptoglobin depletion, hemoglobinuria, and delayed urine hemosiderinuria; extravascular hemolysis occurs in splenic/hepatic cords, yielding prominent spherocytes, unconjugated hyperbilirubinemia, and elevated urine urobilinogen without hemoglobinuria.

Hemoglobinopathies involve qualitative globin chain mutations: HbS (beta-6 Glu->Val) forms insoluble polymer tactoids under deoxygenation, while HbC (beta-6 Glu->Lys) forms hexagonal bar crystals; alkaline electrophoresis (pH 8.4) migrates C-S-F-A, whereas acid electrophoresis (pH 6.2) separates HbS from HbD/G and HbC from HbE/O-Arab in an F-A-S-C pattern.

Last updated: October 2026

Anemias: Classification, Iron Deficiency, Megaloblastic, Hemolytic, and Hemoglobinopathies

Anemia is defined clinically as a reduction below reference limits in the concentration of circulating hemoglobin, hematocrit, or total red blood cell mass, resulting in reduced oxygen delivery to tissues. Diagnostic investigation of anemia requires integrating quantitative automated red cell indices, peripheral smear cytomorphology, biochemical markers of iron kinetics and hemolysis, and hemoglobin molecular characterization. For MTLE licensure candidates, mastery of diagnostic algorithms separating microcytic, macrocytic, and hemolytic anemias is essential.

1. Classification of Anemias: Morphologic vs Kinetic Frameworks

Two complementary systems are employed in clinical hematology to classify anemias: DIAGNOSTIC ANEMIA CLASSIFICATION

  • ┌───────────────────────────────┐
  • │ ANEMIA DIAGNOSIS │
  • │ (↓ Hb, ↓ Hct, ↓ RBC count) │
  • └───────────────┬───────────────┘
  • │
  • ┌─────────────────────────────┴─────────────────────────────┐
  • ▼ ▼
  • ┌───────────────────────────────┐ ┌───────────────────────────────┐
  • │ KINETIC CLASSIFICATION │ │ MORPHOLOGIC CLASSIFICATION │
  • │ (Marrow Response / RPI) │ │ (MCV / RBC Size) │
  • └───────────────┬───────────────┘ └───────────────┬───────────────┘
  • │ │
  • ┌─────────┴─────────┐ ┌─────────────┼─────────────┐
  • ▼ ▼ ▼ ▼ ▼
  • ┌───────────┐ ┌───────────┐ ┌───────────┐ ┌───────────┐ ┌───────────┐
  • │ Hypoprolif│ │ Hyperpro- │ │Microcytic │ │Normocytic │ │Macrocytic │
  • │ (RPI < 2) │ │ liferative│ │(MCV <80fL)│ │(80-100 fL)│ │(MCV>100fL)│
  • │ IDA, ACD, │ │ (RPI > 2) │ │ IDA, ACD, │ │ Acute loss│ │ Megalobl. │
  • │ Aplastic │ │ Hemolysis,│ │ Thalas, │ │ Aplastic, │ │ Non-meg. │
  • │ │ │ Acute loss│ │ Siderobl. │ │ Hemolytic │ │ (B12, Fol)│
  • └───────────┘ └───────────┘ └───────────┘ └───────────┘ └───────────┘
  • Kinetic Classification (Bone Marrow Response)

Assesses whether anemia results from decreased red cell production (hypoproliferation) or increased red cell destruction/loss (survival defect / hemorrhage):

Corrected Reticulocyte Count (CRC) : CRC (%) = Reticulocyte (%) × ( Patient’s Hematocrit 45 ) \text{CRC (\%)} = \text{Reticulocyte (\%)} \times \left( \frac{\text{Patient's Hematocrit}}{45} \right) CRC (%) = Reticulocyte (%) × ( 45 Patient’s Hematocrit ​ )

Reticulocyte Production Index (RPI) : Corrects for the premature release of "stress reticulocytes" from marrow into circulation, which prolongs peripheral blood reticulocyte maturation from 1 day up to 2.5 days: RPI = CRC Maturation Factor (days) \text{RPI} = \frac{\text{CRC}}{\text{Maturation Factor (days)}} RPI = Maturation Factor (days) CRC ​ (Maturation factor: Hct 45% = 1.0; Hct 35% = 1.5; Hct 25% = 2.0; Hct 15% = 2.5)

RPI < 2 \text{RPI} < 2 RPI < 2 : Hypoproliferative anemia; ineffective erythropoiesis or impaired bone marrow response (e.g., IDA, aplastic anemia, ACD, marrow infiltration).

RPI > 2 \text{RPI} > 2 RPI > 2 (or > 3 >3 > 3 ) : Hyperproliferative response; adequate compensatory bone marrow erythropoiesis (e.g., active hemolysis, acute blood loss after resuscitation).

Morphologic Classification (Mean Cell Volume)

Microcytic Hypochromic ( M C V < 80 fL MCV < 80\text{ fL} MC V < 80 fL , M C H C < 32 g/dL MCHC < 32\text{ g/dL} MC H C < 32 g/dL ) : Defective hemoglobin production.

Normocytic Normochromic ( M C V 80 – 100 fL MCV\ 80\text{--}100\text{ fL} MC V 80 – 100 fL , M C H C 32 – 36 g/dL MCHC\ 32\text{--}36\text{ g/dL} MC H C 32 – 36 g/dL ) : Acute hemorrhage, hemolysis, aplastic anemia, early anemia of chronic disease, renal failure.

Macrocytic ( M C V > 100 fL MCV > 100\text{ fL} MC V > 100 fL ) : Megaloblastic (DNA synthesis defect) vs non-megaloblastic (membrane lipid accumulation).

2. Differential Diagnosis of Microcytic Hypochromic Anemias

Four major clinical disorders produce microcytic hypochromic red cells. Accurately distinguishing them requires analyzing serum iron, total iron-binding capacity (TIBC), transferrin saturation, serum ferritin, and erythrocyte indices.

1. Iron Deficiency Anemia (IDA)

Pathophysiology : Most common anemia worldwide. Progresses through three distinct sequential stages:

Stage 1: Iron Store Depletion : Bone marrow hemosiderin stores and serum ferritin decrease (<15 ng/mL) . Serum iron, TIBC, and red cell indices remain normal. Ferritin is the most sensitive and specific single biochemical index of early depleted iron stores.

Stage 2: Iron Deficient Erythropoiesis : Depleted storage iron compromises transport. Serum iron drops, TIBC rises, transferrin saturation falls below 15%, and Free Erythrocyte Protoporphyrin (FEP / Zinc Protoporphyrin ZPP) accumulates due to lack of iron for ferrochelatase insertion. Red cell morphology remains normocytic.

Stage 3: Frank Iron Deficiency Anemia : Microcytic hypochromic anemia develops with decreased Hb/Hct, low MCV, low MCHC, and markedly elevated RDW (>15.0%) . Smear demonstrates microcytic hypochromic cells, prominent pencil/cigar cells , and occasional target cells.

2. Anemia of Chronic Disease / Inflammation (ACD)

Pathophysiology : Driven by chronic systemic inflammation, infections, autoimmune disorders (e.g., rheumatoid arthritis), or malignancies. Inflammatory cytokines—primarily Interleukin-6 (IL-6) —stimulate hepatocytes to synthesize and secrete hepcidin , the master iron-regulatory peptide hormone.

Hepcidin Mechanism : Hepcidin binds directly to the basolateral iron exporter ferroportin-1 on duodenal enterocytes and reticuloendothelial macrophages, inducing its internalization, ubiquitination, and lysosomal degradation.

Consequence : Iron absorption in the gut is blocked, and recycled iron derived from senescent RBCs is trapped inside macrophage storage pools. Erythroid precursors are starved of functional iron despite abundant total body iron stores.

Laboratory Profile : Low serum iron, decreased or low-normal TIBC (transferrin is a negative acute-phase reactant), normal to elevated serum ferritin (ferritin is a positive acute-phase reactant), normal transferrin saturation ( 15 % to 25 % 15\%\text{ to }25\% 15% to 25% ), and normal RDW.

3. Sideroblastic Anemia

Pathophysiology : Defective synthesis of protoporphyrin IX or abnormal incorporation of iron into the heme ring. Can be hereditary (X-linked mutation in erythroid-specific δ \delta δ -aminolevulinate synthase, ALAS2 ) or acquired (lead poisoning, alcohol toxicity, myelodysplastic syndrome with ring sideroblasts, MDS-RS driven by SF3B1 mutations).

Diagnostic Hallmark : Bone marrow examination stained with Perls' Prussian blue demonstrates ring sideroblasts —erythroblasts containing ≥ 5 \ge 5 ≥ 5 Prussian-blue-positive siderotic iron granules encircling one-third or more of the nucleus, representing iron trapped within abnormal perinuclear mitochondria.

Laboratory Profile : Elevated serum iron, elevated transferrin saturation ( > 50 % to 80 % >50\%\text{ to }80\% > 50% to 80% ), markedly elevated serum ferritin, and bone marrow hemosiderin excess. Peripheral smear exhibits a dimorphic erythrocyte population (microcytic hypochromic cells coexisting with normocytic or macrocytic cells), coarse basophilic stippling, and Pappenheimer bodies.

4. Thalassemia Syndromes (Quantitative Globin Defects)

Thalassemias represent hereditary hemolytic disorders characterized by quantitative reduction or complete absence of synthesis of normal globin peptide chains (alpha or beta chains):

Beta-Thalassemia Syndromes

Beta-Thalassemia Minor (Trait) : Heterozygous reduction in β \beta β -chain synthesis ( β / β + \beta/\beta^+ β / β + or β / β 0 \beta/\beta^0 β / β 0 ). Clinical presentation is mild, asymptomatic microcytic anemia.

Key Diagnostic Features : Disproportionately high RBC count ( > 5.0 × 10 12 / L >5.0 \times 10^{12}/\text{L} > 5.0 × 1 0 12 / L ) despite low hemoglobin ( 10 – 12 g/dL 10\text{--}12\text{ g/dL} 10 – 12 g/dL ); very low MCV ( 55 – 72 fL 55\text{--}72\text{ fL} 55 – 72 fL ); normal RDW ( 11.5 % – 14.5 % 11.5\%\text{--}14.5\% 11.5% – 14.5% ).

Mentzer Index : MCV RBC count (millions/ μ L) \frac{\text{MCV}}{\text{RBC count (millions/}\mu\text{L)}} RBC count (millions/ μ L) MCV ​ . A value < 13 <13 < 13 strongly favors thalassemia trait, whereas a value > 13 >13 > 13 strongly points toward iron deficiency anemia.

Hemoglobin Electrophoresis : Diagnostic elevation of H b A 2 > 3.5 % HbA_2 > 3.5\% H b A 2 ​ > 3.5% (typically 4.0 % to 7.0 % 4.0\%\text{ to }7.0\% 4.0% to 7.0% ; normal 1.5 % – 3.5 % 1.5\%\text{--}3.5\% 1.5% – 3.5% ) and slightly elevated H b F HbF H b F ( 1 % to 3 % 1\%\text{ to }3\% 1% to 3% ).

Beta-Thalassemia Major (Cooley's Anemia) : Homozygous complete absence or extreme reduction of β \beta β -chain production ( β 0 / β 0 \beta^0/\beta^0 β 0 / β 0 or β + / β + \beta^+/\beta^+ β + / β + ). Excess unbound free α \alpha α -chains precipitate within erythroid precursors, causing severe intramedullary apoptosis (ineffective erythropoiesis) and severe peripheral extravascular hemolysis.

Clinical Features : Severe transfusion-dependent microcytic anemia appearing at 6 months of age (as fetal HbF switches to adult HbA), massive hepatosplenomegaly, skeletal deformities ("hair-on-end" skull radiograph, maxillary hyperplasia), and iron overload/hemosiderosis.

Smear and Electrophoresis : Marked anisopoikilocytosis, abundant target cells, teardrop cells, prominent nucleated RBCs (metarubricytes), and basophilic stippling. Electrophoresis reveals H b F HbF H b F comprising 70 % to 95 % 70\%\text{ to }95\% 70% to 95% of total hemoglobin, with total absence or trace amounts of HbA.

Alpha-Thalassemia Syndromes

Alpha-globin chains are encoded by four genes (two on each chromosome 16: α α / α α \alpha\alpha/\alpha\alpha αα / αα ). Alpha-thalassemias typically result from gene deletions:

Classification Genotype Functional α \alpha α Genes Clinical and Laboratory Manifestations

Silent Carrier − α / α α -\alpha/\alpha\alpha − α / αα 3 Clinically normal; normal red cell indices; normal electrophoresis in adults.

Alpha-Thal Minor (Trait) − α / − α -\alpha/-\alpha − α / − α (trans) or − − / α α --/\alpha\alpha − − / αα (cis) 2 Mild microcytic hypochromic anemia; high RBC count; normal adult electrophoresis. Note: cis deletion ( − − / α α --/\alpha\alpha − − / αα ) is prevalent in Southeast Asian / Filipino populations, carrying high risk for Hydrops Fetalis in offspring.

Hemoglobin H Disease − − / − α --/-\alpha − − / − α 1 Moderate-to-severe chronic hemolytic anemia ( H b 7 – 10 g/dL Hb\ 7\text{--}10\text{ g/dL} H b 7 – 10 g/dL ), splenomegaly. Excess beta chains form unstable tetramers: Hemoglobin H ( β 4 \beta_4 β 4 ​ ) . Incubation with brilliant cresyl blue precipitates β 4 \beta_4 β 4 ​ tetramers into multiple fine, blue inclusions producing a classic "golf-ball" or "bowling-ball" appearance. Electrophoresis reveals 5 % to 30 % H b H 5\%\text{ to }30\%\ HbH 5% to 30% H b H (fast-migrating anodal band).

Hb Barts Hydrops Fetalis − − / − − --/-- − − / − − 0 Total absence of α \alpha α -chain synthesis. Excess gamma chains form tetramers: Hemoglobin Barts ( γ 4 \gamma_4 γ 4 ​ ) . γ 4 \gamma_4 γ 4 ​ tetramers possess extreme oxygen affinity ( P 50 ≈ 12 mmHg P_{50} \approx 12\text{ mmHg} P 50 ​ ≈ 12 mmHg ), releasing virtually no oxygen to tissues. Results in severe fetal hypoxia, massive ascites, hepatosplenomegaly, high-output congestive heart failure, and death in utero or immediately postpartum.

Microcytic Anemias Laboratory Differential Matrix

Parameter Iron Deficiency Anemia (IDA) Anemia of Chronic Disease (ACD) Beta-Thalassemia Minor Sideroblastic Anemia

Serum Iron Markedly Decreased ( < 30 μ g/dL <30\ \mu\text{g/dL} < 30 μ g/dL ) Decreased Normal to Elevated Markedly Elevated

TIBC Elevated ( > 400 μ g/dL >400\ \mu\text{g/dL} > 400 μ g/dL ) Decreased ( < 250 μ g/dL <250\ \mu\text{g/dL} < 250 μ g/dL ) Normal Normal to Decreased

Transferrin Saturation Markedly Decreased ( < 15 % <15\% < 15% ) Normal to Decreased ( 15 – 25 % 15\text{--}25\% 15 – 25% ) Normal to Elevated Markedly Elevated ( > 50 % >50\% > 50% )

Serum Ferritin Markedly Decreased ( < 15 ng/mL <15\text{ ng/mL} < 15 ng/mL ) Normal to Elevated ( > 100 ng/mL >100\text{ ng/mL} > 100 ng/mL ) Normal to Elevated Markedly Elevated ( > 300 ng/mL >300\text{ ng/mL} > 300 ng/mL )

RDW Elevated ( > 15.0 % >15.0\% > 15.0% ) Normal ( 11.5 – 14.5 % 11.5\text{--}14.5\% 11.5 – 14.5% ) Normal ( 11.5 – 14.5 % 11.5\text{--}14.5\% 11.5 – 14.5% ) Elevated (Dimorphic)

Mentzer Index > 13 > 13 > 13 Variable < 13 < 13 < 13 Variable

Marrow Sideroblasts Absent ( 0 % 0\% 0% ) Decreased ( < 10 % <10\% < 10% ) Normal Ring Sideroblasts ≥ 15 % \ge 15\% ≥ 15%

3. Macrocytic Anemias: Megaloblastic vs Non-Megaloblastic

Macrocytic anemias ( M C V > 100 fL MCV > 100\text{ fL} MC V > 100 fL ) are divided into megaloblastic and non-megaloblastic etiologies based on the mechanism of cellular enlargement: MACROCYTIC ANEMIA WORKUP

  • ┌───────────────────┐
  • │ MCV > 100 fL │
  • └─────────┬─────────┘
  • │
  • ┌─────────────────────────┴─────────────────────────┐
  • ▼ ▼
  • ┌─────────────────────────────┐ ┌─────────────────────────────┐
  • │ MEGALOBLASTIC ANEMIA │ │ NON-MEGALOBLASTIC MACROCYTE│
  • │ (Impaired DNA Synth) │ │ (Preserved DNA Synth) │
  • └──────────────┬──────────────┘ └──────────────┬──────────────┘
  • │ │
  • Nuclear-cytoplasmic dyssynchrony • Round macrocytes (normal N:C)
  • Macro-ovalocytes, pancytopenia • Normal neutrophil segmentation
  • Hypersegmented neutrophils (≥5) • Normal LD, normal homocysteine
  • Ineffective erythropoiesis (↑↑LD) • Causes: Liver disease, alcohol,
  • │ reticulocytosis, hypothyroidism
  • ┌───────┴───────┐
  • ▼ ▼
  • ┌─────────────┐ ┌─────────────┐
  • │ Vitamin B12 │ │ Folate │
  • │ Deficiency │ │ Deficiency │
  • └──────┬──────┘ └──────┬──────┘
  • │ │
  • ↑ Homocysteine• ↑ Homocysteine
  • ↑↑ MMA (Spec.)• Normal MMA
  • Neuro symptoms• NO neuro sx
  • Pernicious An (anti-IF / APCA)
  • Megaloblastic Anemia: Pathophysiology and Morphology

Pathogenesis : Arises from deficient coenzymes required for DNA thymidine monophosphate ( d T M P dTMP d TMP ) synthesis—specifically Vitamin B12 (Cobalamin) or Folate (Vitamin B9) . While nuclear DNA replication stalls, cytoplasmic RNA and protein synthesis proceed at normal rates. This produces classic nuclear-cytoplasmic dyssynchrony : immature, delicate, lacy nuclear chromatin coexisting with abundant, hemoglobinized cytoplasm.

Peripheral Blood Smear Hallmarks :

Macro-ovalocytes : Large, oval-shaped erythrocytes lacking central pallor.

Neutrophil Hypersegmentation : Presence of ≥ 5 % \ge 5\% ≥ 5% of circulating neutrophils containing 5 or more distinct nuclear lobes , or the presence of a single neutrophil with 6 or more lobes . Hypersegmented neutrophils are the earliest and most reliable morphologic indicator of megaloblastic transformation.

Pancytopenia : Concomitant leukopenia and thrombocytopenia with giant platelets.

Ineffective Erythropoiesis : Intense intramedullary apoptosis of megaloblastic erythroblasts releases intracellular enzymes, causing profound elevations in Lactate Dehydrogenase (LD, predominantly LD-1 and LD-2) , elevated indirect bilirubin, and reduced haptoglobin.

Biochemical Differentiation: Vitamin B12 vs Folate Deficiency

Both deficiencies cause megaloblastic macrocytic anemia and elevated plasma homocysteine. However, they are biochemically and clinically distinguished by Methylmalonic Acid (MMA) and neurologic status:

Homocysteine Pathway : Both B12 (methylcobalamin) and N 5 N^5 N 5 -methyl-THF are required to convert homocysteine to methionine via methionine synthase. Hence, total homocysteine is elevated in BOTH B12 and folate deficiencies .

Methylmalonyl-CoA Pathway : Vitamin B12 (adenosylcobalamin) is the mandatory coenzyme for methylmalonyl-CoA mutase , converting methylmalonyl-CoA to succinyl-CoA. In B12 deficiency, methylmalonic acid cannot be metabolized, causing markedly elevated serum and urine Methylmalonic Acid (MMA) . In folate deficiency, MMA remains strictly normal.

Neurologic Consequences : Vitamin B12 deficiency leads to defective myelin sheath maintenance, causing Subacute Combined Degeneration (SCD) of the posterior and lateral columns of the spinal cord (loss of vibration and position sense, paresthesias, spastic ataxia, dementia). Neurologic symptoms occur in B12 deficiency but are absent in folate deficiency . Administering folate to a B12-deficient patient corrects the hematologic anemia but allows irreversible neurologic destruction to progress.

Pernicious Anemia (PA) : Autoimmune destruction of gastric parietal cells leading to achlorhydria and absence of Intrinsic Factor (IF) . Characterized by diagnostic autoantibodies: Anti-Intrinsic Factor antibodies (Types I and II; highly specific) and Anti-Parietal Cell Antibodies (APCA; sensitive but less specific).

Non-Megaloblastic Macrocytic Anemias

Characterized by round macrocytes , normal neutrophil segmentation, normal LD, and absence of nuclear-cytoplasmic dyssynchrony. Major etiologies include:

Chronic Liver Disease and Alcoholism : Excessive membrane surface area caused by accumulation of unesterified cholesterol and phospholipids in the outer lipid bilayer.

Reticulocytosis : Elevated reticulocytes ( M C V 110 – 130 fL MCV\ 110\text{--}130\text{ fL} MC V 110 – 130 fL ) transiently increase the automated MCV.

Hypothyroidism and Aplastic Anemia .

4. Hemolytic Anemias: Intravascular vs Extravascular Hemolysis

Hemolytic anemias are characterized by accelerated premature destruction of erythrocytes (lifespan < 120 days <120\text{ days} < 120 days ). Hemolysis is categorized anatomically based on the site of destruction: HEMOLYSIS PATHWAY COMPARISON

  • INTRAVASCULAR HEMOLYSIS EXTRAVASCULAR HEMOLYSIS
  • (RBC Lysis in Blood Vessels) (Phagocytosis in Spleen/Liver)
  • │ │
  • ▼ ▼
  • Free Hemoglobin Macrophage Lysis
  • │ │
  • ┌───────────┴───────────┐ ▼
  • ▼ ▼ Heme Oxygenase Cleavage
  • Haptoglobin Binding Renal Filtration │
  • │ │ ▼
  • ▼ ▼ Protoporphyrin Ring
  • Markedly Absent Hemoglobinuria │
  • Serum Haptoglobin │ ▼
  • ▼ Unconjugated Bilirubin
  • Tubular Uptake │
  • │ ▼
  • ▼ ↑ Plasma Indirect Bilirubin
  • Hemosiderinuria │
  • (Prussian Blue) ▼
  • ↑ Urine / Fecal Urobilinogen

Diagnostic Parameter Intravascular Hemolysis Extravascular Hemolysis

Primary Anatomical Site Inside blood vessels (endovascular shearing, complement MAC attack) Monocyte-macrophage reticuloendothelial system (spleen and liver cords)

Typical Etiologies PNH, ABO hemolytic transfusion reaction, MAHA (TTP/DIC), cold agglutinin (severe), snake venom Hereditary spherocytosis, warm AIHA (IgG), delayed transfusion reactions, sickle cell anemia

Peripheral Smear Hallmarks Schistocytes , helmet cells, microspherocytes Prominent spherocytes , ovalocytes, polychromasia

  • Serum Haptoglobin Markedly Decreased or Absent (<10 mg/dL) Normal to mildly decreased
  • Plasma Free Hemoglobin Markedly Elevated (Hemoglobinemia) Normal to trace elevated
  • Urine Free Hemoglobin Positive (Hemoglobinuria) : Dark red/brown urine Negative

Urine Hemosiderin Positive : Prussian blue positive granules in tubular epithelial cells (4-7 days post-event) Negative

  • Serum Bilirubin Mildly elevated indirect bilirubin Markedly Elevated Unconjugated (Indirect) Bilirubin
  • Urine Urobilinogen Normal to mildly elevated Markedly Elevated
  • Serum Lactate Dehydrogenase Markedly Elevated (10- to 20-fold) Mildly to moderately elevated
  • Splenomegaly Rare / Absent Prominent / Hallmark finding
  • 5. Qualitative Hemoglobinopathies: Sickle Cell Syndromes, HbC, and HbE

Hemoglobinopathies arise from point mutations altering globin polypeptide amino acid sequences, modifying hemoglobin solubility, electrical charge, or oxygen affinity.

1. Sickle Cell Anemia (Hemoglobin S)

Molecular Genetics : Point mutation in the β \beta β -globin gene at codon 6: replacement of hydrophilic glutamic acid with hydrophobic valine ( β 6 Glu → Val \beta6\text{ Glu}\to\text{Val} β 6 Glu → Val ). Genotype: Homozygous HbSS (Sickle Cell Disease) or Heterozygous HbAS (Sickle Cell Trait).

Pathophysiology : When deoxygenated, the nonpolar valine binds a complementary hydrophobic pocket on the adjacent β \beta β -chain, causing polymer tactoid formation, sickling, microvascular vaso-occlusion, tissue infarction, and autosplenectomy (leaving Howell-Jolly bodies).

Laboratory Screening Tests :

Sodium Metabisulfite Test : A 2% sodium metabisulfite solution deoxygenates hemoglobin on a sealed glass slide, inducing sickling visible under light microscopy within 15 to 30 minutes.

Sodium Dithionite Tube Solubility Test : Erythrocytes are lysed in a concentrated phosphate buffer solution containing sodium dithionite (reducing agent) and saponin. Deoxygenated HbS is insoluble in high-molarity phosphate buffer, forming a cloudy, turbid suspension that obscures black reader lines on a background chart. Soluble hemoglobins (HbA, HbF) leave a clear, transparent solution.

Limitations : Does NOT differentiate HbSS disease from HbAS trait; false negatives occur in infants < 6 months <6\text{ months} < 6 months (predominant HbF) or patients with severe anemia ( H b < 7.0 g/dL Hb < 7.0\text{ g/dL} H b < 7.0 g/dL ); false positives occur in multiple myeloma or extreme hyperlipidemia.

2. Hemoglobin C (HbC)

Molecular Genetics : Point mutation at codon 6 of the β \beta β -globin gene substituting positively charged lysine for glutamic acid ( β 6 Glu → Lys \beta6\text{ Glu}\to\text{Lys} β 6 Glu → Lys ).

Morphology : Intracellular dehydration produces numerous target cells and pathognomonic HbC crystals —dense, dark, hexagonal, oblong, or "bar-of-gold" crystals within the cell cytoplasm, particularly evident in post-splenectomy patients.

3. Hemoglobin E (HbE)

Molecular Genetics : Point mutation at codon 26 of the β \beta β -globin gene substituting lysine for glutamic acid ( β 26 Glu → Lys \beta26\text{ Glu}\to\text{Lys} β 26 Glu → Lys ).

Epidemiology : Extremely prevalent in mainland Southeast Asia (Thailand, Cambodia, Laos, Myanmar). It is less common in Filipinos, among whom alpha-thalassemia deletions (including the --SEA and --FIL types) are the leading inherited hemoglobin disorder. HbE causes mild microcytic hypochromic red cells with prominent target cells. When co-inherited with β \beta β -thalassemia (HbE/ β \beta β -thalassemia), it manifests as a severe thalassemia major phenotype.

4. Dual-pH Hemoglobin Electrophoresis

Definitive clinical identification of hemoglobinopathies relies on combining Alkaline Cellulose Acetate Electrophoresis and Acid Citrate Agar Electrophoresis : HEMOGLOBIN ELECTROPHORESIS PATTERNS

  • ALKALINE ELECTROPHORESIS (pH 8.4 - 8.6, Cellulose Acetate)
  • Cathode (-) ──────────────────────────────────────────────> Anode (+)
  • C S F A
  • (HbC, A2, (HbS, D, (HbF) (HbA)
  • HbE, O) HbG)
  • "Crawls" "Slow" "Fast" "Accelerates"
  • ACID ELECTROPHORESIS (pH 6.0 - 6.2, Citrate Agar)
  • Cathode (-) ──────────────────────────────────────────────> Anode (+)
  • F A S C
  • (HbF) (HbA, D, (HbS) (HbC)
  • HbG, E, O)
  • "Fast" "Accelerates" "Slow" "Crawls"

Alkaline Electrophoresis (pH 8.4 to 8.6) : At alkaline pH, hemoglobin molecules carry net negative charges and migrate toward the anode (+). Net charge differences drive migration: Cathode ( − ) ⟶ C ⟶ S ⟶ F ⟶ A ⟶ Anode ( + ) \text{Cathode } (-) \longrightarrow \mathbf{C} \longrightarrow \mathbf{S} \longrightarrow \mathbf{F} \longrightarrow \mathbf{A} \longrightarrow \text{Anode } (+) Cathode ( − ) ⟶ C ⟶ S ⟶ F ⟶ A ⟶ Anode ( + )

Mnemonic : C rawls, S low, F ast, A ccelerates.

Comigrations at Alkaline pH : HbA2, HbC, HbE, and HbO-Arab co-migrate to the "C" position; HbS, HbD-Los Angeles, and HbG-Philadelphia co-migrate to the "S" position.

Acid Citrate Agar Electrophoresis (pH 6.0 to 6.2) : Essential secondary confirmation. Citrate agar separation depends on the specific stereochemical affinity of hemoglobin variants for agaropectin in the agar gel rather than net electrical charge: Cathode ( − ) ⟶ F ⟶ A ⟶ S ⟶ C ⟶ Anode ( + ) \text{Cathode } (-) \longrightarrow \mathbf{F} \longrightarrow \mathbf{A} \longrightarrow \mathbf{S} \longrightarrow \mathbf{C} \longrightarrow \text{Anode } (+) Cathode ( − ) ⟶ F ⟶ A ⟶ S ⟶ C ⟶ Anode ( + )

Resolution : HbS separates cleanly from HbD and HbG (which migrate with HbA); HbC separates cleanly from HbE and HbO-Arab (which migrate with HbA).